BACKGROUND Data demonstrating the outcome of transcatheter aortic valve replacement (TAVR) in the very elderly
. A disease-specific health status survey originally developed to describe and monitor health status in patients with heart failure, the KCCQ has also been validated in patients with aortic stenosis (13) . For this study, we focused on the overall summary score of the 12-item Kansas City Cardiomyopathy Questionnaire (KCCQ-os), which ranges from 0 to 100 with higher scores indicating less symptom burden, less physical and social limitations, and better quality of life. The Cox proportional hazards models were used to assess the unadjusted and adjusted effects of age on 30-day and 1-year mortality. Nonfatal outcomes were assessed using Fine and Gray proportional subdistribution hazards models in the presence of competing risk of death (14, 16) . The multivariable models included the covariates in the recently developed TVT model for in-hospital mortality (unpublished data). The risk of adverse outcomes for patients $90 years versus <90 years of age was reported using hazard ratios (HRs) with 95% CIs.
Complete case analysis was performed for 30-day and 1-year KCCQ-os scores. KCCQ-os scores were summarized as medians with interquartile ranges and compared between patients $90 and <90 years of age using the Wilcoxon rank sum test. The effect of age on follow-up KCCQ-os scores was assessed using linear regression models that included a binary indicator variable for age group. Models were constructed as unadjusted (including age only) and adjusted, including age, baseline STS PROM score, and baseline KCCQ-os score. As the STS PROM score is calculated including age as well as its interactions with several risk factors, this complicates the multivariable adjustment. As such, the baseline STS PROM score Compared to patients <90 years of age, nonagenarians were more likely to be female and less likely to have high-risk features including prior nonaortic valve cardiac surgery procedure, diabetes, prior stroke, and prior MI, but overall, they had higher estimated surgical mortality (STS PROM scores, age $90 years vs.
<90 years: 9.2% vs. 6.3%; p < 0.001). Although nonagenarians had slower 5-m walk tests (8.7 s vs. 8.0 s; p < 0.001), they had better self-reported QOL (KCCQ-os: 41.7 vs. 37.5; p < 0.001) prior to TAVR ( Table 1) .
IN-HOSPITAL OUTCOMES. Compared with patients <90 years of age, nonagenarians were more likely to experience in-hospital stroke, major vascular assess site complications, and major bleeding events ( Table 2) . They also had longer intensive care unit stays and increased rates of blood transfusions. In-hospital death was higher among nonagenarians (6.5% vs.
4.5%; p < 0.001), and they were also more likely to be discharged to extended care/transitional care unit/ rehabilitation or nursing home.
POST-DISCHARGE OUTCOMES. No differences in stroke rate, aortic valve reintervention, or MI were evident after 30 days or 1 year ( Table 3 , Figures 1   and 2 ). There was a higher rate of heart failure readmission after 30 days for nonagenarians (5.3% vs. Arsalan et al. Cumulative incidence of stroke in nonagenarians and patients younger than age 90 years. (18) . We found a lower 30-day mortality rate in nonagenarians (8.8%), which may reflect differences in patient selection and improvements in devices and techniques. Although the mortality rate for nonagenarians in our study remained higher than that observed in younger patients (5.9%), this rate may be acceptable, particularly given the QOL benefits observed among surviving nonagenarians. This is further illustrated by the similar observed-toexpected ratios. Of note, the observed nonagenarian mortality rate is not only lower than that previously reported on nonagenarians, but is also comparable to published mortality rates for octogenarians (18, 19) .
TAVR in Nonagenarians
In regard to long-term survival, the FRANCE-2 data showed a trend toward decreased survival in older patients, but the study did not meet statistical significance due to the limited number of patients at risk by 1 year (18) . The current study confirms a higher mortality rate in nonagenarians at 1 year, but due to the high mortality rates in both groups, it is doubtful that the measured difference of 2.8% is clinically significant or simply reflects the shorter underlying life expectancy of nonagenarians. Some clarity on this issue can be achieved by comparing our 1-year outcomes to the life expectancy of an age-matched general population. The younger patient cohort showed a 1-year mortality of 22%, which is significantly higher compared with the age-matched general population (6.1% in males and 4.4% in females) (20) . In nonagenarians, however, the observed difference between 1-year mortality in TAVR patients (24.8%) and the sameage general population (male 20.5% and female
16.5%) was much smaller (Central Illustration).
Thus, we confirm the promising results from other reports about TAVR in select nonagenarians, and we additionally show that the difference between outcomes of select nonagenarians and younger patients might not be of major clinical relevance.
We further describe the outcomes of a very small cohort of patients $100 years of age undergoing TAVR.
Overall, 24 centenarians were treated in the TVT registry; thus, this is the largest report on TAVR in this age group. We are aware that our patient cohort Cumulative incidence of heart failure readmission in nonagenarians and patients younger than age 90 years. Additional in-hospital complications that differed between nonagenarians and younger patients were major bleeding events, need for blood transfusion, and stroke, all of which were higher in the nonagenarian group. The in-hospital stroke rate was higher for nonagenarians in the present study, but we did not detect any significant effect of age on incidence of stroke following TAVR at 30 days or at 1 year (9, 18, 22) . The observed 30-day stroke rate was similar to prior reports on elderly patients undergoing TAVR (6, 9, 19, 22, 23) . The increased incidences of these in- rates were higher in this age group compared with younger TAVR patients, the absolute and relative differences were clinically modest. Furthermore, although nonagenarians generally take longer to recover their physical function and QOL than younger patients, TAVR improved long-term QOL to a similar degree in both age groups. As such, the reported data support both the safety and the efficacy of TAVR in select elderly patients, suggesting that TAVR should not be denied solely on the basis of patient age.
